Emergent Biosolutions Inc.
About
8.15USD+0.09 +1.12%
Closed • Updated at 13:34 GMT+00:00Market Cap$420.51M
Volume614.6K
Beta2.91
RSI44.94
Gross Margin44.44%
Emergent Biosolutions Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 30 2026
Emergent BioSolutions Reports First Quarter 2026 Financial Results
Apr 30 2026
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
Apr 29 2026
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Apr 28 2026
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Apr 16 2026
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026